Related Experiment Video
Updated: Jun 15, 2026
The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
Published on: June 1, 2019
Therapeutic sentinel lymph node imaging
Stefan S Kachala1, Elliot L Servais, Bernard J Park
1Division of Thoracic Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Abstract:
Improving existing means of sentinel lymph node identification in non-small cell lung cancer will allow for molecular detection of occult micrometastases that may cause recurrence in early stage non-small cell lung cancer. Furthermore, targeted application of chemical and biological cytotoxic agents can potentially improve outcomes in patients with lymph node (LN) metastases. "Therapeutic Sentinel Lymph Node Imaging" incorporates these modalities into a single agent thereby identifying which LNs harbor tumor cells and simultaneously eradicating metastatic disease. In this review, we summarize the novel preclinical agents for identification and treatment of tumor bearing LNs and discuss their potential for clinical translation.
Insights
New agents for "Therapeutic Sentinel Lymph Node Imaging" can identify and treat cancerous lymph nodes in early-stage non-small cell lung cancer, potentially preventing recurrence.
Area of Science:
- Oncology
- Medical Imaging
- Nanotechnology
Background:
- Early-stage non-small cell lung cancer (NSCLC) recurrence is often linked to occult micrometastases in sentinel lymph nodes (LNs).
- Current methods for sentinel lymph node identification in NSCLC lack the sensitivity for detecting minimal metastatic disease.
- Targeted cytotoxic agents offer potential for improved outcomes in patients with lymph node metastases.
Purpose of the Study:
- To review novel preclinical agents for "Therapeutic Sentinel Lymph Node Imaging" in non-small cell lung cancer.
- To explore agents that simultaneously identify and eradicate tumor-bearing lymph nodes.
- To discuss the clinical translation potential of these innovative agents.
Main Methods:
- Review of preclinical research on combined imaging and therapeutic agents for sentinel lymph nodes.
- Analysis of agents targeting molecular detection of micrometastases.
- Evaluation of cytotoxic agents for eradicating metastatic disease within lymph nodes.
Main Results:
- Development of novel agents that integrate sentinel lymph node identification with targeted cancer cell eradication.
- Preclinical evidence suggests these agents can detect and treat tumor-involved lymph nodes.
- These agents hold promise for reducing recurrence in early-stage NSCLC.
Conclusions:
- "Therapeutic Sentinel Lymph Node Imaging" represents a promising strategy for managing lymph node metastases in NSCLC.
- Further development and clinical translation of these agents could significantly improve patient outcomes.
- This approach may enable precise treatment of micrometastatic disease, preventing cancer recurrence.
